By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


NxStage/Fresenius Likely Next Test for Divided Commission

The U.S. Federal Trade Commission has been reviewing Fresenius’ $2 billion acquisition of NxStage Medical for nearly a year and a half, making it the longest deal under review at the agency.featured

Nonessential FTC Employees to be Furloughed

At 11:59 p.m. on December 28, 2018, nonessential employees at the U.S. Federal Trade Commission will be furloughed as a result of the government shutdown, the regulatory agency confirmed to CTFN.featured

NxStage/Fresenius Merger: FTC Update

A recommendation to approve a consent order that would allow Fresenius to move forward with its acquisition of NxStage moved from the Federal Trade Commission’s Bureau of Competition to thefeatured

Fresenius Appears to Make Progress at FTC with NxStage Merger

An attorney working with a third party told CTFN that Fresenius and NxStage have strong arguments and that the companies are making their case well tofeatured

Fresenius Has Not Certified Compliance for NxStage Medical Acquisition

CTFN confirmed with a source close to the deal that Fresenius has not certified substantial compliance with the U.S. Federal Trade Commission’s second request, as some marketfeatured

Market Definition Key in NxStage/Fresenius Merger Review

Market definition will be key in Germany-based Fresenius Medical Care’s $2 billion deal to acquire US-headquartered NxStage Medical, antitrustfeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.